Curated News
By: NewsRamp Editorial Staff
August 26, 2026
Monod Bio and SignalChem Biotech Forge Licensing Deal for AI-Designed Proteins
TLDR
- SignalChem Biotech gains a competitive edge by licensing Monod Bio's LuxSit luciferase and NovoBodies for custom assays, enhancing its CRO offerings.
- The non-exclusive agreement allows SignalChem to integrate Monod Bio's AI-designed LuxSit luciferase and NovoBodies into custom luminescent assay development for research use.
- This partnership accelerates research by providing high-quality discovery candidates, potentially leading to faster development of life-saving diagnostics and treatments.
- Monod Bio's LuxSit is an AI-designed luciferase, engineered for robust biosensors, and NovoBodies are compact binding proteins for high-performance recognition.
Impact - Why it Matters
This licensing agreement is important because it brings Monod Bio's cutting-edge AI-designed proteins—LuxSit luciferase and NovoBodies—into the hands of researchers through SignalChem Biotech's established CRO services. By integrating these advanced tools into custom assay development, the partnership promises to accelerate drug discovery and life science research. For scientists, this means faster access to high-quality discovery candidates, more efficient workflows, and the ability to tackle complex biological questions with innovative tools. For the broader industry, it signals a growing trend of AI-enabled technologies being adopted by major life science companies, potentially transforming how research is conducted and leading to breakthroughs in diagnostics and therapeutics.
Summary
Seattle-based AI-enabled protein design company Monod Bio and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement. The deal allows SignalChem Biotech to incorporate Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies into its custom luminescent assay development and protein-fusion services for third-party researchers. This collaboration expands SignalChem’s specialized CRO capabilities and supports Sino Biological’s broader strategy of integrating AI-enabled technologies into its global life science tools and services portfolio.
Under the agreement, SignalChem Biotech can now offer customized assays that leverage Monod Bio’s AI-designed proteins, enabling researchers to obtain high-quality discovery candidates more rapidly. Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the value of the partnership: “By incorporating Monod Bio’s AI-designed protein technologies into SignalChem’s custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly.” Monod Bio’s LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance target recognition. Together, they provide versatile tools for developing customized assays and discovery workflows.
Daniel Silva Manzano, PhD, CEO of Monod Bio, expressed enthusiasm about the partnership, noting that SignalChem Biotech and Sino Biological have the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base. “This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services,” he said. The collaboration marks a significant step in making advanced AI-designed proteins accessible to the life science research community, potentially accelerating drug discovery and research programs worldwide.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Monod Bio and SignalChem Biotech Forge Licensing Deal for AI-Designed Proteins
